Ambati A, Boas L S V, Ljungman P, Testa L, de Oliveira J F, Aoun M, Colturato V, Maeurer M, Machado C M
1] Division of Hematology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden [2] Centre for Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital, Stockholm, Sweden.
Virology Laboratory (LIM 52-HCFMUSP), Institute of Tropical Medicine, University of São Paulo, São Paulo, Brazil.
Bone Marrow Transplant. 2015 Jun;50(6):858-64. doi: 10.1038/bmt.2015.47. Epub 2015 Mar 23.
Pretransplant influenza vaccination of the donor or allogeneic hematopoietic SCT (HSCT) candidate was evaluated in a randomized study. One hundred and twenty-two HSCT recipients and their donors were assigned to three randomization groups: no pretransplant vaccination (n=38), donor pretransplant vaccination (n=44) or recipient pretransplant vaccination (n=40). Specific IgG was assessed by both hemagglutinin inhibition (HI) and, in 57 patients, by an indirect influenza-specific ELISA at specified times after HSCT. Vaccinated donors had seroprotective HI titers for Ags H1 and H3 (P<0.001) compared with the other groups at the time of donation. The titers against H1 (P=0.028) and H3 (P<0.001) were highest in the pretransplant recipient vaccination group until day 180 after transplantation. A significant difference was found in the specific Ig levels against pandemic H1N1 at 6 months after SCT (P=0.02). The mean IgG levels against pandemic H1N1 and generic H1N1 and H3N2 were highest in the pretransplant recipient vaccination group. We conclude that pretransplant recipient vaccination improved the influenza-specific seroprotection rates.
在一项随机研究中对供体或异基因造血干细胞移植（HSCT）候选者进行移植前流感疫苗接种进行了评估。122名HSCT受者及其供体被分配到三个随机分组：移植前未接种疫苗（n = 38）、供体移植前接种疫苗（n = 44）或受者移植前接种疫苗（n = 40）。在HSCT后的特定时间，通过血凝抑制（HI）以及对57名患者采用间接流感特异性ELISA来评估特异性IgG。与其他组相比，接种疫苗的供体在捐献时针对抗原H1和H3具有血清保护性HI滴度（P<0.001）。直到移植后180天，移植前受者接种疫苗组针对H1（P = 0.028）和H3（P<0.001）的滴度最高。在SCT后6个月，针对大流行性H1N1的特异性Ig水平存在显著差异（P = 0.02）。移植前受者接种疫苗组针对大流行性H1N1以及通用型H1N1和H3N2的平均IgG水平最高。我们得出结论，移植前受者接种疫苗提高了流感特异性血清保护率。
